Macro Group Pharmaceuticals - Macro Capital S.A.E results, Q4 2025
Net profit, assets, equity and cash flow for Q4 2025, against the same period a year earlier, from the published financial statements.
Net profit116 millionEGP · +403.8% vs the same period a year earlier
Total assets778 millionEGP · +26.4% vs the same period a year earlier
Shareholders' equity194 millionEGP · +148.3% vs the same period a year earlier
In short
- Macro Group Pharmaceuticals - Macro Capital S.A.E's net profit for Q4 2025 was about 116 million EGP, up +403.8% from -38.1 million EGP in Q4 2024.
- Total assets at the end of Q4 2025 were about 778 million EGP, and shareholders' equity about 194 million EGP.
Key lines against the same period a year earlier
This periodQ4 2024Change
Net profit116 million-38.1 million+403.8%
Gross profit627 million340 million+84.3%
Total assets778 million615 million+26.4%
Total liabilities584 million537 million+8.7%
Shareholders' equity194 million78.1 million+148.3%
Total liabilities and equity778 million615 million+26.4%
Operating cash flow—-74.45 million—
Investing cash flow-22.88 million18.56 million−223.3%
Financing cash flow-19.59 million42.92 million−145.7%
Net change in cash—-12.97 million—
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Macro Group Pharmaceuticals - Macro Capital S.A.E's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy